Name: Pharmaqo Labs MK2866 Ostarine 60 x 25mg
SKU: 358
Price: 38.00 GBP
Availability: InStock

Pharmaqo Labs MK2866 Ostarine 60 x 25mg

Pharmaqo Labs MK2866 Ostarine 60 x 25mg delivers a precise oral formulation of Ostarine, the most extensively researched selective androgen receptor modulator (SARM) available. This compound demonstrates exceptional efficacy for increasing lean body mass without inducing androgenic activity in non-skeletal muscle tissue. Each package contains 60 capsules dosed at 25mg, providing substantial supply for extended research protocols examining tissue-selective anabolic effects. The 25mg concentration represents an optimized research dose, enabling accurate protocol implementation for studies investigating muscle preservation, growth, and metabolic enhancement in controlled models.

Ostarine distinguishes itself through remarkable tissue selectivity. Unlike traditional anabolic-androgenic steroids, MK-2866 activates androgen receptors in skeletal muscle and bone while demonstrating minimal activity in prostate, sebaceous glands, and other androgen-sensitive tissues. This selectivity profile makes Pharmaqo Labs MK2866 Ostarine 60 x 25mg invaluable for researchers examining targeted anabolic signaling without systemic androgenic complications. Studies consistently demonstrate significant lean mass accretion, with typical gains of 5-7lbs observed over 6-week protocols, with extension to 8 weeks possible without the severe on-cycle side effects associated with steroidal compounds.

The compound’s mechanism mirrors testosterone and steroids at the receptor level, yet avoids downstream complications. By binding androgen receptors and altering gene expression, Ostarine increases protein synthesis and drives muscle hypertrophy. However, the tissue-selective nature prevents prostate enlargement and secondary sexual organ stimulation, creating a cleaner research profile for specific applications.

Mechanism of Action

Selective AR Binding: Ostarine binds androgen receptors in skeletal muscle and bone with high affinity.
Tissue-Specific Activation: Demonstrates minimal activity in prostate, liver, and skin tissues.
Gene Expression Alteration: Modulates transcription of anabolic genes supporting protein synthesis.
Protein Synthesis Enhancement: Increases translational efficiency and amino acid incorporation in muscle tissue.
Osteoblast Stimulation: Promotes bone formation and mineral density in skeletal structures.
Myogenic Differentiation: Supports satellite cell activation and muscle fiber hypertrophy.
Non-Steroidal Structure: Avoids conversion to DHT or estrogen, eliminating aromatization complications.

Metabolic Impact

Research utilizing Pharmaqo Labs MK2866 Ostarine 60 x 25mg reveals significant physiological effects:

Lean Mass Accretion: 5–7lb gains typical over 6-week protocols; sustainable over 8 weeks.
Muscle Preservation: Prevents catabolism during caloric restriction and disuse conditions.
Bone Density Enhancement: Increased mineralization and reduced osteoporosis markers.
Fat Loss Promotion: Improved body composition through enhanced metabolic rate and nutrient partitioning.
Insulin Sensitivity: Improved glucose uptake and metabolic flexibility in studied models.
Lipid Profile: Favorable effects on cholesterol parameters compared to steroidal alternatives.
Recovery Acceleration: Reduced tissue damage and faster repair kinetics post-exertion.

Key Features

Most Anabolic SARM: Superior tissue-selective anabolic activity in research literature.
Tissue Selectivity: Minimal androgenic effects in non-skeletal muscle tissues.
Optimized Dosing: 25mg capsules enable precise, consistent administration.
Extended Supply: 60-capsule format supports longer protocols without resupply.
Oral Bioavailability: Convenient administration with excellent absorption kinetics.
Extended Cycle Capability: 8–week protocols possible without severe side effect profiles.
Verified Purity Standards: Manufactured under strict protocols with independent batch testing.

Product Specifications

Product Name: Pharmaqo Labs MK2866 Ostarine
Active Ingredient: Ostarine (MK-2866)
Chemical Classification: Selective Androgen Receptor Modulator (SARM)
Dosage Strength: 25mg per capsule
Pack Size: 60 capsules
CAS Number: 841205-47-8
Molecular Formula: C19H14F3N3O3
Appearance: White to off–white capsules
Standard Protocol: 25mg daily for 6-8 weeks
Storage Requirements: Store at 15°C-25°C; protect from light, moisture, and heat
Shelf Life: 3 years from manufacture date (as indicated on packaging)
Legal Status: Research chemical / Not for human consumption (Regulations vary by jurisdiction)

Where to Buy

Acquiring genuine Pharmaqo Labs MK2866 Ostarine 60 x 25mg requires sourcing from authorized distributors to ensure authenticity and safety.

Authorized Suppliers Only: Purchase exclusively from verified Pharmaqo Labs distributors with documented authorization.
Batch Verification: Verify unique batch codes through official Pharmaqo Labs channels before use.
Visual Inspection: Authentic packaging features professional labeling, intact seals, and uniform capsules free of defects.
Avoid Unverified Sources: Do not purchase from social media, underground forums, or vendors lacking proof of authenticity.

Conclusion

Pharmaqo Labs MK2866 Ostarine 60 x 25mg represents the gold standard for SARM research, combining the most extensively validated tissue-selective anabolic compound with precise 25mg dosing and extended 60-capsule supply. The compound’s unique ability to generate significant lean mass accretion—typically 5–7lbs over 6 weeks—while avoiding androgenic complications in non-target tissues distinguishes it from traditional steroidal approaches. The extended 8–week research window without severe on-cycle effects provides flexibility unavailable with conventional anabolics. Studies benefit from Ostarine’s dual action on muscle and bone, supporting applications in sarcopenia, osteoporosis, and metabolic disease research. The non-steroidal structure eliminates aromatization and 5-alpha–reductase concerns, simplifying protocol design. Researchers must remain attentive to dose-dependent testosterone suppression and implement appropriate post-cycle protocols.